|
1 Personalized Medicine
In the clinical practice you are probably the personification of personalized healthcare. In your practice, on an individual patient basis, it has to be decided which protocol will benefit the patient most. The concept of Personalized medicine fits like a glove to this task. With the introduction of more targeted medicines, such as monoclonal antibodies and kinase inhibitors, even more treatment options are expected to become available in the coming years. However, from your practice, you also know that there is no such thing as a wonder drug and this area of medicine needs to be further developed.
In PamGene’s experience, comparing our interactions with the many stakeholders in the healthcare chain, the Medical Oncologists understands best what the concept of Personalized medicine can bring to the patient.
The Medical Oncologist, supported by the pathologist, will have a crucial role in the further development of Personalized medicine.
The Medical Oncologists that are active in Oncology Associations have an important role in endorsing the new Personalized medicine solutions in their discussions with both insurance companies and the drug development industry.
By studying the available literature, it is clear that the maturation of Personalized medicine will work out in a very positive way for individual patients, with benefits for the healthcare system. However, the Personalized medicine concept is in need of support and flexibility by all healthcare stake holders and introduction of this concept needs creative solutions. Medical Oncologists, supported by pathologists, are key to making this happen.
2 Matching Medicines
PamGene’s instrumentation measure tens to hundreds of protein characteristics in patient samples such as binding activities (the PamChip® Nuclear Hormone Receptor program) and enzymatic activities (the PamChip® Kinase program). This makes it possible to perform in vitro studies to show the effects of medicines on the protein activities released from clinical samples.
Matching Medicines ultimately aims to provide medical oncologists with valuable data that predicts an individual's response to a specific drug prior to treatment. This guides the selection of likely responders to a specific drug and avoids non-responders experiencing unnecessary side effects and lost time. PamGene’s technology is perfectly suited to play an important role in the decision tree, together with other clinical observations and tests, because it enables testing of the medicine on the kinases released from patients’ material. This opens up the possibility of generating important information based on the individual’s patient kinase-medicine interaction. The three practical applications are:
- Therapy selector
Help in therapy choice in cases where multiple registered kinase inhibitors exist.
- Patient selector
Introducing a new way of patient selection for a registered drug
- Matched clinical trials
Testing of efficacy of registered drugs for new indications.
Kinase activity and kinase inhibition effects have been observed with PamGene’s Matching Medicines technology across a broad range of cancer tissue types. These include, breast, blood, bone marrow, brain, cerebrospinal fluid, colon, prostate, oesophagus, kidney, lung, ovarian, rectal and skin.
3. PamGene
How can PamGene help you to investigate new protocols for target medicines?
- PamGene can help monitor relevant kinase activities and their interactions with medicines.
- PamGene can be a window to gaining access to the most up to date targeted medicine information and experience.
- Using PamGene’s technology will differentiate your trial proposal from competition.
- Gain from helping PamGene to develop its business.
4. Becoming part of PamGene’s network
How to work with PamGene
PamGene can act as a standard service provider and can perform commercial testing services for you. Our commercial management can provide you with a quotation for such a service.
Alternatively, if you are working in one of our key areas, PamGene would certainly consider performing collaborative work with you. For our collaborators we perform sample testing and bioinformatics analysis. This could be based on a complete new plan or you could become a part of an ongoing collaborative project. All of this work starts by contacting us and agreeing on a joint plan.
PamGene’s management can be easily reached to discuss the conditions of such a project. We have experience with technology transfer offices worldwide. Our goal is always to agree on a contract that is seen as fair and balanced by all parties involved.
Rob Ruijtenbeek
Vice President Biological Sciences and our head of research
(
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
)
+31 (0)736158089
John Lindsay
Vice President US Sales
(
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
)
1 508 269 9048
Arje Brilleman
Director Sales Europe
(
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
)
+31 (0)736158077
|
